Imperium Debt Financing


 
TIDMENTL




  Entelos, Inc.




  Imperium Debt Financing




  On December 21, 2007, Entelos, Inc. ("Entelos" or the "Company") entered into a debt financing agreement with Imperium Master Fund, LTD ("Imperium") in which Imperium provided the Company $6,500,000 in total cash loan proceeds. Entelos and Imperium are currently in active negotiation to restructure the debt financing. Entelos and Imperium have amended the terms of the secured debt in order to allow the parties until April 30, 2009 to finalize the revised terms of the existing debt financing arrangements.




  About Entelos




  Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical, health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.

Entelos Regs (LSE:ENTL)
過去株価チャート
から 5 2024 まで 6 2024